Claims for Patent: 11,020,389

Summary for Patent: 11,020,389

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	17/061,047
Patent Claims:	1. A method of treating major depressive disorder, comprising: orally administering a dosage form once a day or twice a day for at least seven consecutive days, to a human being suffering from major depressive disorder, wherein the dosage form contains, as the only therapeutically active compounds in the dosage form, about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, and about 90 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion. 2. The method of claim 1, wherein the dosage form contains about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, and wherein the dosage form is orally administered twice a day. 3. The method of claim 1, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, and wherein the dosage form is orally administered twice a day. 4. The method of claim 1, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, and wherein the dosage form is orally administered twice a day. 5. The method of claim 1, wherein the dosage form is orally administered twice a day. 6. The method of claim 1, wherein dextromethorphan hydrobromide, or the free base form or another salt form of dextromethorphan, comprises a deuterium-modified dextromethorphan. 7. The method of claim 1, wherein the dosage form comprises about 45 mg of dextromethorphan hydrobromide and about 105 mg of bupropion hydrochloride. 8. The method of claim 1, wherein the dosage form is orally administered once a day for the first 3 days; and is orally administered twice a day thereafter. 9. The method of claim 8, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, and about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. 10. The method of claim 8, wherein the dosage form comprises about 45 mg of dextromethorphan hydrobromide and about 105 mg of bupropion hydrochloride. 11. The method of claim 1, wherein the human being is suffering from treatment-resistant depression. 12. The method of claim 11, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and wherein the dosage form is orally administered twice a day. 13. The method of claim 11, wherein the dosage form contains about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, and about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and wherein the dosage form is orally administered twice a day. 14. The method of claim 11, wherein the dosage form is orally administered twice a day. 15. The method of claim 11, wherein the dosage form comprises about 45 mg of dextromethorphan hydrobromide and about 105 mg of bupropion hydrochloride. 16. The method of claim 11, wherein the dosage form is orally administered once a day for the first 3 days; and is orally administered twice a day thereafter. 17. The method of claim 16, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, and about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. 18. The method of claim 16, wherein the dosage form comprises about 45 mg of dextromethorphan hydrobromide and about 105 mg of bupropion hydrochloride.